Home Health Corona Pandemic GSK’s RSV vaccine succeeds in late-stage trial for older adults

GSK’s RSV vaccine succeeds in late-stage trial for older adults


GSK’s vaccine for respiratory syncytial virus (RSV) succeeded in an ongoing late-stage trial involving older adults, the company said on Friday.

It is the first trial to show statistically significant efficacy for RSV in adults aged 60 years and older, the British drugmaker said, adding that it expects to submit regulatory applications for the RSV vaccine in the second half of 2022.

The RSV vaccine is a key component of the British drugmaker’s plans to boost its drug development success rate as it prepares to spin off its consumer health venture next month as an independent listed company called Haleon.

GSK then aims to focus solely on vaccines and prescription drugs.

RSV is a leading cause of pneumonia in toddlers and the elderly, but vaccine development has been plagued by setbacks for decades.

GSK in February halted enrolment in three RSV trials involving pregnant women after it had paused the studies following undisclosed safety recommendations from an independent committee.

In the trial with older adults, GSK said that no unexpected safety concerns were observed in the interim analysis.

Credits – Source – https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/gsks-rsv-vaccine-succeeds-in-late-stage-trial-for-older-adults/articleshow/92124031.cms



Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.